| NKCx Histopathological outcome* within 12 months after cervix cytology in 2024 |
| 621 Västernorrland |
| Benign | LSIL | HSIL | AIS | Cancer | Other | PAD missing | Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cytologi | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benign sample | 61 | 12.1% | 33 | 6.5% | 8 | 1.6% | 1 | 0.2% | . | . | . | . | 401 | 79.6% | 504 | 100.0% |
| ASCUS | 72 | 42.4% | 59 | 34.7% | 19 | 11.2% | 1 | 0.6% | . | . | 2 | 1.2% | 17 | 10.0% | 170 | 100.0% |
| LSIL | 47 | 34.3% | 51 | 37.2% | 25 | 18.2% | . | . | . | . | 4 | 2.9% | 10 | 7.3% | 137 | 100.0% |
| Atypical glandular cells/AGC | 2 | 15.4% | 2 | 15.4% | 3 | 23.1% | 5 | 38.5% | 1 | 7.7% | . | . | . | . | 13 | 100.0% |
| ASC-H | 1 | 7.7% | 5 | 38.5% | 7 | 53.8% | . | . | . | . | . | . | . | . | 13 | 100.0% |
| HSIL | 1 | 4.2% | 6 | 25.0% | 17 | 70.8% | . | . | . | . | . | . | . | . | 24 | 100.0% |
| Totalt | 184 | 21.4% | 156 | 18.1% | 79 | 9.2% | 7 | 0.8% | 1 | 0.1% | 6 | 0.7% | 428 | 49.7% | 861 | 100.0% |
| NOTE: Histopathological outcome from T83x taken into account. |
| This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
| * Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
| The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
| Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
| Snomed codes in the category Cancer: |
|---|
| M81403 |